Ezzat El Hassadi, MD, University Hospital Waterford, Waterford, Ireland, discusses the treatment strategies available for patients with multiple myeloma in Ireland. Dr El Hassadi explains that after undergoing induction therapy, patients with multiple myeloma are then considered for transplantation, continuous maintenance therapy, or where possible, clinical trials. Dr El Hassadi also highlights the common combinational therapies used, including the triplet of lenalidomide, bortezomib, and dexamethasone (RVD), and how patient performance status is carefully monitored to determine the efficacy of the treatment strategy. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.